For Dr. Renato Martins, the theme that Seattle Cancer Care Alliance chose for the American Society of Clinical Oncology's annual meeting -- "tomorrow's treatments today” -- is more than just a catchy slogan. It’s his life’s work, illustrated by a clinical trial that was instrumental in changing the way that lung cancer patients are treated.
When Michael Rankin’s shoulder started hurting him two years ago, he didn’t hesitate to get it checked out. First he was referred to physical therapy. Then when the pain didn’t decrease, he got an X-ray, which eventually led to an MRI and biopsy that revealed the ultramarathon runner had stage 4 lung cancer.
More than a dozen Seattle Cancer Care Alliance (SCCA) and Fred Hutch physicians and researchers who are leaders in breast oncology will be at the San Antonio Breast Cancer Symposium December 4-8. The symposium provides the latest information on the experimental biology, etiology, prevention, diagnosis and therapy of breast cancer and premalignant breast disease.
SCCA among first cancer treatment centers in country - and only in NW - to offer axi-cel (YESCARTA™) -- ground-breaking new immunotherapy
Seattle Cancer Care Alliance (SCCA) has been a leader in immunotherapy since it was first introduced as a form of treatment for certain cancers decades ago. Today, we’ve been selected as the only certified treatment center in the Northwest to offer axicabtagene ciloleucel (axi-cel, also known by the brand name YESCARTA™), a new immunotherapy that uses engineered cell therapy to harnesses the power of a patient’s own immune system to treat adults with aggressive non-Hodgkin lymphoma (NHL).
Developments about former President Jimmy Carter’s melanoma diagnosis and the subsequent story about his positive response to treatment has made me pause and reflect on the extraordinary progress in a remarkably short period of time, both in the treatment of what used to be considered one of the most deadly cancers and in the very rapid advancement of immunotherapy. In August 2015, President Carter was diagnosed with Stage IV melanoma that had spread to his liver and brain. He had surgery for the tumors in the liver and focused radiation for those in his brain followed by immunotherapy with a drug – pembrolizumab – classified as an anti-PD-1 antibody. A happy update indicated that President Carter was having an excellent response to the immunotherapy: there have been no new tumors.